Company with headquarters in Germany, on Monday, December 2, announced that it is buying the pharmaceutical business Biopharma, one of the leading pharmaceutical manufacturers in Ukraine.
the agreement provides for the acquisition of production capacity in the city of Bila Tserkva (Kyiv region). Shareholders Biopharma will retain the plasma business and focus on its development both in Ukraine and abroad. This acquisition is subject to execution of the standard terms, in particular to permit the merger in Ukraine, and is expected to be completed in December 2019.
as a result of this acquisition, STADA has implemented one of the largest financial investments in the pharmaceutical sector of Ukraine is today one of the largest foreign investments in the country recently.
"We see great potential in the Ukrainian market. Following this acquisition we will become a powerful player in the Ukrainian pharmaceutical market with strong local production", - said General Director of STADA Peter Goldschmidt.
"For Ukraine, the arrival of such an investor is a milestone event. New jobs and pay taxes instead of importing goods and selling them here. And yet it is access to the best technology, research and development, as well as to export markets", - said the Prime Minister Alexey Goncharuk.
He added that the decision STADA to enter the Ukrainian market is the growth of confidence in Ukraine from the international business. In turn, attracting foreign investment is one of the key factors of economic growth, which is key to the well-being of every Ukrainian.
Biopharma is a leading pharmaceutical company founded over 100 years ago, has expanded rapidly in 2014, building two modern plant in Bila Tserkva, meet the requirements of good manufacturing practice (GMP).
August 15, the sole shareholder of PJSC "Biopharma" engaged in the manufacture of preparations from donor blood, has decided to liquidate the company in connection with the unsatisfactory condition of receipt of financial flows from business operations.
STADA Arzneimittel AG is a public company with headquarters in bad Vilbel (Germany). The company is focused on two areas: generic drugs, in particular the special drugs and OTC drugs.